Prostate cancer (PCa) is the most prevalent cancer, a significant contributor to morbidity and
a leading cause of cancer-related death in men in Western industrialized countries. In …

Androgen receptor (AR) signaling remains the major oncogenic pathway in prostate cancer
(PCa). Androgen-deprivation therapy (ADT) is the principle treatment for locally advanced …

Background The prostate gland is the most common site of cancer and the second leading
cause of cancer mortality in American men. It is well known that epigenetic alterations such …

Prostate cancer is a major health burden within the ever-increasingly aging US population.
The molecular mechanisms involved in prostate cancer are diverse and heterogeneous. In …

BACKGROUND Prostate cancer is the most commonly diagnosed cancer among men in
North America and is a leading cause of death. Standard treatments include androgen …

In spite of progress in diagnosis and treatment, prostate cancer has become one of the most
frequent lethal cancers in males in many Western industrialized countries. Research on the …

The molecular genetics of prostate cancer, the second most common cause of cancer-
related death in men, is poorly understood. Inherited factors are believed to account for 42 …

CONTEXT: Prostate cancer (PCa) is one of the most common human malignancies and
arises through genetic and epigenetic alterations. Epigenetic modifications include DNA …

Highlights•Patients who receive antiandrogen treatments are more likely to develop
CRPC.•A genomic landscape study has identified aberrant epigenetic events in CRPC and …

Prostate cancer is the most common noncutaneous malignancy and the second leading
cause of cancer death among men in the United States. DNA methylation and histone …